ArticleMolecular cancer therapeutics2025

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.

Lawrence B Snyder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.